FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 379 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC MOST POPULAR Cancer Rehabilitation Starts at Diagnosis: Part II July 13, 2021 EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... September 25, 2023 EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib July 29, 2021 5 ways cancer can impact sexual wellbeing May 17, 2023 Load more HOT NEWS FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma Making a startup out of a scientist Grieving for Your Old Life After Cancer Is CBD Safe for People With Cancer?
